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Background: To identify risk factors for being a “reduced responder” to ranibizumab treatment in a clinical setting
in patients with neovascular age-related macular degeneration.
Methods: This retrospective study included 165 eyes of 165 consecutive patients with choroidal neovascularisation
secondary to neovascular, age-related macular degeneration. Eyes were treated with three intravitreal injections of
ranibizumab, followed by PRN (pro re nata) dosing thereafter. All patients were reevaluated every four weeks and
then followed for six months. Reduced responders were defined as patients with a loss in visual acuity of at least 1
visual acuity line at the last follow-up and/or persistent intraretinal or subretinal fluid or detectable choroidal
neovascularisation at the last follow-up, compared to baseline.
Results: Overall, 58 out of 165 eyes (35.2%) were considered to be reduced responders to treatment at the end of
follow-up. The initial CNV size at baseline was correlated with the risk of being a reduced responder at the end of
follow-up (p = 0.017).
Conclusion: We identified the initial lesion size as a predictor for a reduced response to treatment in this study.
Patients with a large initial lesion size should be thoroughly informed about the possible poorer response to the
intravitreal treatment.
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Ranibizumab is a humanised antigen-binding fragment
(Fab) that targets all isoforms of vascular endothelial
growth factor A (VEGF-A) and is approved by the Food
and Drug Administration for the treatment of patients
with neovascular age-related macular degeneration
(AMD), as well as diabetic macular oedema and macular
oedema following retinal vein occlusion. Randomised
phase-III clinical trials (Minimally Classic/Occult Trial
of the Anti-VEGF Antibody Ranibizumab In the Treat-
ment of Neovascular Age-Related Macular Degeneration
[Marina] and Anti-VEGF Antibody for the Treatment of
Predominantly Classic Choroidal Neovascularisation in
Age-Related Macular Degeneration [ANCHOR]) showed* Correspondence: christina.korb@unimedizin-mainz.de
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reproduction in any medium, provided the ora reduction in retinal thickness and maintained visual
acuity gains with monthly intravitreal injections of 0.3
and 0.5 mg of ranibizumab for treating minimally classic,
occult and predominantly classic CNV secondary to AMD
[1,2]. The “Prospective Optical Coherence Tomography
(OCT) Imaging of Patients with Neovascular Age-Related
Macular Degeneration (AMD) Treated with intraOcular
Ranibizumab [PrONTO]” trial explored an alternate dos-
ing strategy of intravitreal ranibizumab for all types of sub-
foveal CNV secondary to AMD. Patients underwent three
consecutive monthly injections followed by PRN (pro re
nata) dosing thereafter [3]. After twelve months, visual
acuity improved 15 or more letters in 35% of patients [3].
However, publications about the limited response to
anti-VEGF treatment are rare; the “reduced responder”
poses challenges to clinicians, and there is no general
consensus on how a reduced response is defined. There
are very few current predictors of visual outcome.d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cular macular degeneration consisted of three consecutive
injections of ranibizumab, followed by PRN dosing there-
after in a clinical setting. In a clinical setting, we investi-
gated the determinants of a reduced response to treatment,
defined as patients who revealed a reduction in visual acu-
ity of at least 1 visual acuity line and/or persistent or re-
current retinal fluid or choroidal neovascularisation after
six months of treatment, compared to baseline, after pri-
mary intravitreal ranibizumab therapy for choroidal neo-
vascular lesions secondary to AMD.
Methods
This retrospective data analysis was conducted at the
Department of Ophthalmology, University Medical Centre
of Johannes Gutenberg-University of Mainz, Germany. In
total, 165 eyes of 165 consecutive patients with choroidal
neovascularisation secondary to neovascular age-related
macular degeneration who were treated within a nine-
month time frame and completed the six-month follow-
up were included in the study. Eyes were treated with
three monthly injections of ranibizumab (Lucentis;
Novartis, Nürnberg, Germany; 0.5 mg/0.05 ml) followed
by PRN dosing. Retreatments occurred in case of progres-
sion (vision loss of at least 1 visual acuity line, increase in
macular oedema of >100 μm, persistent leakage in fluores-
cein angiography, clinically detectable new haemorrhages).
All patients were reevaluated every four weeks and then
followed for six months. Approval from the local ethics
committee was sought and waived due to the study’s
retrospective nature. The study followed the tenets of the
Declaration of Helsinki.
All lesion types were included in the study. No patient
had undergone prior treatment or received additional
therapy for neovascular AMD during follow-up.
Eyes received treatment after a complete ocular exam-
ination, including a best corrected distance visual acuity
test (Snellen chart, BCVA was converted into logarithm
of the minimum angle of resolution (logMAR) for statis-
tical analysis), slit lamp examination, Goldmann appla-
nation tonometry, binocular ophthalmoscopy, fundus
colour photography, optical coherence tomography (fast
macular thickness acquisition protocol, Stratus OCT,
Zeiss Jena GmbH, Jena, Germany), fluorescein angiog-
raphy (FA, HRA II, Heidelberg Engineering, Heidelberg,
Germany), and indocyanine green angiography (ICGA,
HRA II, Heidelberg Engineering, Heidelberg, Germany).
The size of the CNV in the angiograms (greatest linear
dimension, GLD) was measured on the middle phase
fluorescein angiogram to exclude leakage during any
later phases. Whenever ICG was also performed, those
images were used to identify feeder vessels and to detect
choroidal neovascularisation. Patients were re-scheduled
for follow-up visits every 4 weeks. BCVA, slit lamp andbinocular examinations took place at monthly intervals,
and OCT, FA and ICGA at least every three months.
Before therapy, written informed consent was obtained
from all patients after the potential risks and benefits
of the intravitreal injections had been explained in
detail.
All patients underwent intravitreal injections of ranibi-
zumab via pars plana under topical anaesthesia under
strict aseptic conditions.
Reduced responders were defined as follows:
– loss in visual acuity ≥1 visual acuity line at the last
follow-up compared to baseline and/or
– persistent or recurrent intraretinal or subretinal fluid
or detectable choroidal neovascularisation at the last
follow-up.
As we refer to a “reduced response” in our paper and
not to “non-response”, we applied the quite stringent cri-
teria of any vision loss compared to baseline.
Statistical analysis was performed using SPSS statistical
software (version 18.0, SPSS Inc., Chicago, IL, USA).
A logistic regression model was used to assess the in-
fluence of different variables on response to ranibizumab
therapy. Our primary question was whether the CNV’s
initial size would reveal an influence on the likelihood of
a reduced response at the end of follow-up. Further-
more, we assessed the influence of the presence of an
initial pigment epithelial detachment, initial central ret-
inal thickness, lesion type, patient age and time elapsed
from first examination in the clinic until time of the first
injection.
The level of statistical significance was fixed at α = 0.05
for the primary hypothesis. All other p-values were con-
sidered to be explorative.
Results
A total of 165 eyes of 165 patients were enrolled in this
study, of which 98 patients were female. Patient age
ranged from 56 to 94 years (mean 78 years). All of the
patients completed the six-month follow-up. No major
ocular or systemic adverse events were observed in the
follow-up period.
The lesions were classified as occult with no classic
CNV in 86 eyes (52.1%), minimally classic CNV in 18 eyes
(10.9%), predominantly classic CNV in 38 eyes (23%) and
RAP lesions in the remaining 23 eyes (13.9%); see Figure 1.
At baseline, 20 eyes (12.1%) presented a pigment epithe-
lium detachment. The lesion location was subfoveal in
130 eyes (78.8%), parafoveal in 26 eyes (15.8%), and extra-
foveal in 9 eyes (5.5%).
During the six-month follow-up, the majority of eyes
(135 eyes, 81.8%) received the three consecutive injec-
tions in the first three months of treatment and needed
Figure 1 Proportion of reduced responders (black) and responders (white) in the various CNV types (occult, minimally classic,
predominantly classic and RAP). The type of lesion was not related to the risk of a reduced response to treatment.
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received four injections and in one eye (0.6%), five injec-
tions of ranibizumab.
At baseline, the mean logMAR BCVA was 0.70 ± 0.30
(mean ± SD); the mean visual acuity improved to 0.55 ±
0.30 after the three consecutive injections and was 0.62 ±
0.33 at the end of follow-up; see Figure 2.
The initial foveal thickness was 339 ± 84 μm (mean ±
SD). After the three monthly consecutive injections of rani-
bizumab, this value decreased to 234 ± 59 μm and mea-
sured 280 ± 89 μm at the end of follow-up; see Figure 3.
At baseline, the mean CNV size (GLD, greatest linear
dimension) was 1736 ± 1093 μm (mean ± SD) initially;
338 ± 777 μm, after the first three injections; and 750 ±
885 μm, at the end of follow-up; see Figure 4.
One patient (0.6%) had lost three or more lines of vi-
sion at the end of follow-up, while 29 patients (17.6%)
had gained three or more lines at the end of follow-up
compared to baseline.
According to the criteria listed above, 58 out of 165
eyes (35.2%) were considered to be reduced responders
to the treatment at the end of follow-up, presenting ei-
ther a reduction in visual acuity compared to baseline
and/or persistent intraretinal or subretinal fluid or per-
sistent or recurrent choroidal neovascularisation.
We related the initial CNV size at baseline to the risk
of being a reduced responder at the end of follow-up;
see Figure 1. The OR (odds ratio) was 0.964 per 100 μm
increase of the initial CNV size (GLD) (95% CI, 0.936-
0.993, p = 0.017); see Table 1.Table 1 shows that none of the initial presence of a pig-
ment epithelium detachment (OR 1.728, 95% CI, 0.595-
5.024, p = 0.315), the central retinal thickness at baseline
(OR 0.998, 95% CI, 0.994-1.002, p = 0.362), the lesion type
(OR 0.887, 0.966, 1.597 for minimally classic, predomin-
antly classic, RAP vs. occult, p = 0.820, p = 0.932, p = 0.373,
respectively), the patient age (OR 0.986, 95% CI, 0.943-
1.030, p = 0.513), or the time between the first patient
consultation and the first injection (OR 0.995, 95% CI,
0.981-1.009, p = 0.425) were related to the likelihood of a
reduced response to treatment.
Discussion
We related the responsiveness to intravitreal ranibizu-
mab in our study to the initial lesion size at baseline.
Lux et al. showed that the efficiency of intravitreal beva-
cizumab in patients with neovascular AMD depended
on the initial lesion size [4]. This outcome corresponds
with the findings of the TAP and VIP trials, which also
reported the initial lesion size as an important predictor
of the magnitude of treatment benefit with verteporfin
therapy in occult, with no classic or minimally classic
lesion, compositions [5].
Before the use of ranibizumab, treatments, such as
verteporfin photodynamic therapy (Visudyne, Novartis
Pharmaceuticals, Nürnberg, Germany) and laser photo-
coagulation merely slowed the progression of visual acuity
loss. [6-8]
Although intravitreal injections of ranibizumab have
been shown to be effective in the treatment of neovascular
Figure 3 Change in mean retinal thickness (μm) of reduced responders (black) and responders (white) at baseline (month 0) and after
the first three consecutive injections (month 4) to the end of follow-up (month 6).
Figure 2 Change in mean visual acuity (LogMar) of reduced responders (black) and responders (white) at baseline (month 0) to the
end of follow-up (month 6).
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Figure 4 Change in the mean CNV size (μm) of reduced responders (black) and responders (white) at baseline (month 0) and after the
first three consecutive injections (month 4), until the end of follow-up (month 6).
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ual acuity, and some had lost ≥3 lines of VA by the end of
the MARINA and ANCHOR trials [1,2].
In this study performed in a clinical setting, 35% of the
patients were considered to be reduced responders to
treatment at the end of follow-up, having either reduced
visual acuity compared to baseline and/or persistent
intraretinal or subretinal fluid or persistent or recurrent
choroidal neovascularisation.Table 1 Univariable logistic regression models were used
to assess the influence of different variables (initial CNV
size (GLD), initial PED, initial central retinal thickness,
initial type of lesion, age of patient, time between first
consultation to first injection) on response to
ranibizumab therapy
OR SD (95% CI) p
initial CNV size (GLD) 0.964 0.936-0.993 0.017
initial PED 1.728 0.595-5.024 0.315
initial central retinal thickness 0.998 0.994-1.002 0.362
initial type of lesion
minimally classic vs. occult 0.886 0.312-2.518 0.820
predominantly classic vs. occult 0.966 0.437-2.135 0.932
RAP vs. occult 1.597 0.570-4.471 0.373
age of patient (years) 0.986 0.943-1.030 0.528
time between first consultation
to first injection (days)
0.995 0.981-1.009 0.452
Shown are odds ratios (OR), standard deviations (SD) and p-values.In a cohort receiving as-needed injections of ranibizu-
mab for exudative AMD, visual improvement was related
to the frequency of injections received but not to the
resolution of fluid by OCT [9]. Ahlers and co-workers
identified subretinal fluid as the most relevant factor for
visual function [10].
Brown et al. stated that if a monthly reinjection proto-
col is not used and patients are treated on an as-needed
basis, a combination of clinical examination and qualita-
tive OCT measurements should be used to guide the anti-
VEGF treatment to maximise vision gain [11]. The im-
portance of closely monitoring patients is confirmed by
our study, as 35% of the patients presented a reduction
in visual acuity compared to baseline and/or persistent
intraretinal or subretinal fluid or persistent or recurrent
choroidal neovascularisation at the end of follow-up.
Menghini et al. retrospectively evaluated predictive
factors for being a “good” or “bad” responder to ranibi-
zumab treatment [12]. They found that only the course
of visual acuity in the first three months seems to be of
value for estimating the treatment response; however,
they identified no predictor for response to treatment,
e.g. lesion size [12].
Rosenfeld and co-workers investigated the cause of
visual acuity (VA) loss in patients with neovascular age-
related macular degeneration (AMD) receiving monthly
ranibizumab injections in pivotal ranibizumab phase-III
trials. At month 24, 9% of the ranibizumab-treated patients
from MARINA and 10% of the ranibizumab-treated
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Baseline characteristics associated with VA loss at month
24 included older age, better VA, and larger lesions [13].
Surprisingly, unlike other authors, we did not find a
correlation between age and a reduced response to treat-
ment [13,14]. However, other investigators have also not
found a correlation between age and response to treat-
ment [15]. Our findings should be verified in a larger
population with a longer follow-up.
Defining the proportion of reduced responders in the
MARINA and ANCHOR trials is not entirely possible,
as both report the proportion of patients improving by
more than 15 letters, and the primary end point was the
proportion of patients losing fewer than 15 letters [1,2].
The proportions of patients improving by more than 15
letters were 33.8% for the 0.5 mg group in the MARINA
study and 40.3% for the 0.5 mg group in the ANCHOR
study [1,2]. In our study, only one patient (0.6%) lost three
or more lines of vision at the end of follow-up; con-
versely, 99.4% of patients lost fewer than three lines. In
the MARINA and ANCHOR trials, this proportion was
94.6% in the 0.5 mg group in the MARINA and 96.4%
in the 0.5 mg group in the ANCHOR study [1,2]. In
our study, we observed only 17.6% of patients with
improvement by more than 3 lines, but one must con-
sider that we included all CNV types, including those
with RAP lesions and the 12.1% of patients with a
pigment epithelium detachment at baseline. Thus, the
results are difficult to compare. Reche-Frutos et al. stated
that RAP II lesions with PED and RAP III have an
poorer anatomic and visual evolution than patients
with stage II without PED after ranibizumab therapy [16].
Another difference is that we had a follow-up of six
months, whereas the MARINA and ANCHOR studies
had 12 months of follow-up.
Muether and co-workers found a correlation between
the time elapsed between treatment indication and first
injection and the visual acuity deterioration [17]. Other
authors reported a correlation between visual acuity de-
terioration in 28.4% of patients and a median treatment
delay of 28 days [18]. In our study, the time elapsed be-
tween the diagnosis and the first ranibizumab treatment
was not a predictor of a reduced response to treatment,
according to the criteria listed above. In Germany, pay-
ment for the initial ranibizumab treatment and PRN
treatment must be pre-approved by the patient’s public
health insurance company. In Germany, the predomin-
antly visual acuity-driven ranibizumab retreatment regi-
men is based on the EMA (European Medicines Agency)
drug information, which recommends retreatment after
recurrent vision loss of 5 EDTRS letters. Second, lesion
activity (persistent or recurrent subretinal fluid, in-
crease of pigment epithelium detachment, new haem-
orrhage, recurrent thickening of the retina >100 μm)was recommended as an important criterion for retreat-
ment by the German Ophthalmological Society (DOG), the
Professional Association of German Ophthalmologists
(BVA) and the Retinological Society (RG).
Because we defined reduced responders as patients
with either decreasing visual acuity at the end of follow-
up or a reduced anatomical response to treatment, those
patients who experienced a delay in the onset of therapy
may have already had further alterations in the retinal
pigment epithelium or fibrosis. However, in our study,
visual acuity at baseline was no predictor of a reduced
response to treatment.
Our study is limited by its retrospective nature, and a
further weakness is the limited follow-up of six months.
In Germany, reimbursement for the OCT is not covered
by public health insurance. Therefore, as the patient has
to pay for the OCT, it was not performed every four
weeks. Moreover, the present study did not differentiate
the extent of fibrosis as a predictor for reduced response
to treatment. The presence of active choroidal neovascu-
larisation was an inclusion criterion for enrolment in the
study; thus, further studies investigating the presence
and extent of fibrosis in the analysis of predictors are
needed. Another limitation of our present study is its
short follow-up, as large lesions in this short time period
might not have been sufficiently treated. Furthermore,
large initial lesion sizes might simply reflect a more severe
nature of the disease than smaller lesion sizes, rather than
a reduced response to treatment. Further studies with a
longer follow-up will be necessary to verify whether lesion
size is truly a predictor of reduced response.
The “reduced responder” poses challenges to clinicians,
and there is no general consensus on how “reduced re-
sponders” are defined. The existing studies are very het-
erogeneous, and comparisons with published studies are
difficult. The definition of a “reduced responder” in our
study was chosen as stated above in order to include
patients with decreasing visual acuity at the end of follow-
up, as well as those showing a reduced anatomical re-
sponse to treatment.
Conclusions
In this study performed in a clinical setting, we have iden-
tified initial lesion size as a predictor for a poor treatment
response. It remains difficult to predict patient response
prior to treatment. Intravitreal anti-VEGF treatment for
large lesions is absolutely essential, as untreated, these le-
sions have the potential to cause severe vision loss and fi-
brosis. However, patients with a large initial lesion size
should be thoroughly informed about the potentially
poorer response to the intravitreal treatment.Competing interests
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